MeiraGTx Holdings plc (MGTX): Shareholders' Equity
-$5.79M
As of 2025-12-31
$215.78M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$5.79M | n/m | 2026-03-30, Balance as of period end |
| 2024-12-31 | $67.83M | -50.9% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $138.18M | +17.4% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $117.74M | -36.5% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $185.40M | -22.3% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $238.56M | +25.0% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $190.80M | +135.4% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $81.06M | n/m | 2020-03-11, Balance as of period end |
| 2017-12-31 | -$47.37M | n/a | 2019-03-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$5.79M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $505.66M | -1.0% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $178.13M | -58.3% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.13B | +9.3% |
| Compugen Ltd (CGEN) | 2025-12-31 | $102.73M | +87.1% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $112.21M | +34.7% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $765.28M | -33.5% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$132.45M | n/m |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $158.94M | -1.5% |
Compare MGTX, FDMT, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗